 |
|
|
| |
Utility of FIB-4, MRE, MRI-PDFF, & FibroScan
to Identify Patients With At-risk F2-F3 NASH Based on
Screening Data From a 2000 Patient Biopsy-Confirmed Cohort
of Resmetirom Phase 3 Clinical Trial (MAESTRO-NASH)
|
| |
| |
AASLD 2022 Nov 4-8
Rohit Loomba,1 Stephen A. Harrison,2 Rebecca A. Taub,3 Guy W. Neff,4 Sam Moussa,5 Jörn M. Schattenberg,6 Mazen Noureddin7
1NAFLD Research Center, University of California, San Diego, CA; 2University of Oxford, United Kingdom & Pinnacle Clinical Research, San Antonio, TX;
3Madrigal Pharmaceuticals, Conshohocken, PA; 4Covenant Metabolic Specialists, Sarasota, FL; 5University of Arizona for Medical Sciences & Adobe Gastroenterology, Tucson, AZ; 6Metabolic Liver Research Program, I. Department of Medicine, University Medical Center, Mainz, Germany; 7Houston Research Institute, Houston, TX
|
| |
|
|
|
|
|
